These studies have explored various aspects, including the mechanisms of action of drugs used to treat CRC, such as 5-Fluorouracil, oxaliplatin (Ueno et al., 2013), fentanyl (Zhang et al., 2014), resveratrol (Buhrmann et al., 2017), as well as the pathogenesis of CRC through molecular pathways like p53/miR-101/KPNA3 (Wang et al., 2023), AKT/TM4SF1 (Wang R. et al., 2021), ATGL/ mTOR (Su et al., 2023) and so on. The gene discussed is TP53; the disease is colorectal carcinoma.